

Leaders in Metabolic Disease



Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Key to advancing new drug candidates rapidly is determining how knowledge gained from early metabolic disease research translates to drug action and effects in humans. Celerion leverages its Phase I-IIa experience, expertise and specialized-equipped facilities to investigate early signals of efficacy for new treatments of metabolic-based diseases including diabetes, nonalcoholic steatohepatitis (NASH) and obesity.

Focus on NASH

Celerion offers a breadth of non-invasive services to assess steatosis, inflammation and oxidative stress, and fibrosis. These pharmacodynamic hepatic imaging and soluble biomarkers analyses are essential early signals of drug efficacy to enable faster go/no-go decisions.

- FibroScan®
- Magnetic resonance imaging (MRI) and magnetic resonance elastography (MRE)*
- Validated bioanalytical assays (e.g. CK18, C4 bile acid derivative, IL6, IL1 β , and more)
- Stable label de novo lipogenesis assay
- Liver biopsy*

Focus on Diabetes

From simple HbA1c tracking to specialized procedures, Celerion provides several cost-effective measures of insulin sensitivity to safely and efficiently facilitate your early clinical study.

- Oral glucose tolerance test (OGTT)
- Mixed meal tolerance test (MMTT)
- Continuous glucose monitoring (CGM)

Focus on Obesity and Metabolic Syndrome

We offer several sophisticated pharmacodynamic measurements of advanced body imaging techniques and enhanced energy metabolism to evaluate drug efficacy.

- Dual x-ray absorptiometry (DEXA), weight circumference and bioimpedance
- MRI, ultrasound
- Indirect calorimetry
- Adipose tissue and skeletal muscle biopsy*

*with support from external specialists

Access to Special Populations

Key to the conduct of any clinical study is an effective recruitment strategy of healthy participants and target patient populations.

- Expansive active database of over 128,000 healthy, overweight and obese participants
- Database of participants with metabolic syndrome, prediabetes and type II diabetes
- Ongoing recruitment of participants with fatty liver and liver stiffness, pre-screened with FibroScan®
- Local and national community partners and health-based organizations to gain further access to patient populations

CELERION VALUE

Experience

- Benefit from comprehensive knowledge of specialized metabolic testing methods and hands-on operational experience that supports early Proof-of-Concept in the development of diabetes, obesity, metabolic and cardio-metabolic interventions
- Conducted hundreds of studies and thousands of procedures ensuring robust study designs are developed for optimal success
- Collective experience enables us to anticipate potential issues and address them to deliver high-quality data within clients' timeline

Expertise

- Over a decade of expertise in metabolic diseases ensures the highest standards are applied for the design, conduct and analysis of all studies
- Hands-on experience with a wide range of testing procedures and models to detect early signals of safety or efficacy to support better decision making and delivery of efficient drug development programs